Tags

Type your tag names separated by a space and hit enter

Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice.
Hypertens Res. 2010 Dec; 33(12):1289-97.HR

Abstract

Angiotensin II (AngII) type 1-receptor blockers (ARBs) have been effectively used not only in the treatment of hypertension but also in cardiac protection. However, whether and why there are differences in these effects still remain unclear. Here we compared the effects of five commonly used ARBs (Candesartan, Olmesartan, Losartan, Telmisartan and Valsartan) on pressure overload-induced cardiac hypertrophy in mice model. Pressure overload was produced by constriction of the transverse aorta (TAC) for 2 weeks, which induced a significant elevation of blood pressure; ARBs or saline was administered through a stomach tube; Cardiac hypertrophy was evaluated by transthoracic echocardiography, cardiac histology and specific gene expression analyses. Although all the five ARBs, which did not repress the elevation of left ventricular pressure after TAC, attenuated the development of cardiac hypertrophy in the wild-type mice, the degrees of regression by Candesartan, Olmesartan and Losartan tended to be larger than those by Telmisartan and Valsartan. Furthermore, in angiotensinogen-knockout mice lacking endogenous AngII, TAC-induced cardiac hypertrophy was regressed by Candesartan, Olmesartan and Losartan but not by Telmisartan and Valsartan administration. Our data suggest that Candesartan, Olmesartan and Losartan can effectively inhibit pressure overload-induced cardiac hypertrophy even in the absence of AngII, whereas Telmisartan and Valsartan could exert the inhibitory effects only in the presence of AngII.

Authors+Show Affiliations

Central Laboratory, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20944638

Citation

Li, Lei, et al. "Comparison of Angiotensin II Type 1-receptor Blockers to Regress Pressure Overload-induced Cardiac Hypertrophy in Mice." Hypertension Research : Official Journal of the Japanese Society of Hypertension, vol. 33, no. 12, 2010, pp. 1289-97.
Li L, Zhou N, Gong H, et al. Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res. 2010;33(12):1289-97.
Li, L., Zhou, N., Gong, H., Wu, J., Lin, L., Komuro, I., Ge, J., & Zou, Y. (2010). Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertension Research : Official Journal of the Japanese Society of Hypertension, 33(12), 1289-97. https://doi.org/10.1038/hr.2010.182
Li L, et al. Comparison of Angiotensin II Type 1-receptor Blockers to Regress Pressure Overload-induced Cardiac Hypertrophy in Mice. Hypertens Res. 2010;33(12):1289-97. PubMed PMID: 20944638.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of angiotensin II type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. AU - Li,Lei, AU - Zhou,Ning, AU - Gong,Hui, AU - Wu,Jian, AU - Lin,Li, AU - Komuro,Issei, AU - Ge,Junbo, AU - Zou,Yunzeng, Y1 - 2010/10/14/ PY - 2010/10/15/entrez PY - 2010/10/15/pubmed PY - 2011/3/19/medline SP - 1289 EP - 97 JF - Hypertension research : official journal of the Japanese Society of Hypertension JO - Hypertens Res VL - 33 IS - 12 N2 - Angiotensin II (AngII) type 1-receptor blockers (ARBs) have been effectively used not only in the treatment of hypertension but also in cardiac protection. However, whether and why there are differences in these effects still remain unclear. Here we compared the effects of five commonly used ARBs (Candesartan, Olmesartan, Losartan, Telmisartan and Valsartan) on pressure overload-induced cardiac hypertrophy in mice model. Pressure overload was produced by constriction of the transverse aorta (TAC) for 2 weeks, which induced a significant elevation of blood pressure; ARBs or saline was administered through a stomach tube; Cardiac hypertrophy was evaluated by transthoracic echocardiography, cardiac histology and specific gene expression analyses. Although all the five ARBs, which did not repress the elevation of left ventricular pressure after TAC, attenuated the development of cardiac hypertrophy in the wild-type mice, the degrees of regression by Candesartan, Olmesartan and Losartan tended to be larger than those by Telmisartan and Valsartan. Furthermore, in angiotensinogen-knockout mice lacking endogenous AngII, TAC-induced cardiac hypertrophy was regressed by Candesartan, Olmesartan and Losartan but not by Telmisartan and Valsartan administration. Our data suggest that Candesartan, Olmesartan and Losartan can effectively inhibit pressure overload-induced cardiac hypertrophy even in the absence of AngII, whereas Telmisartan and Valsartan could exert the inhibitory effects only in the presence of AngII. SN - 1348-4214 UR - https://www.unboundmedicine.com/medline/citation/20944638/Comparison_of_angiotensin_II_type_1_receptor_blockers_to_regress_pressure_overload_induced_cardiac_hypertrophy_in_mice_ DB - PRIME DP - Unbound Medicine ER -